Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 13/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12661743 | 1.00 | CDK9 (0.58) | CDK9ALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1849202 | 1.00 | CDK9 (0.58) | CDK9ALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1849368 | 0.91 | CDK9 (0.55) | CDK9ALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1848528 | 0.91 | CDK9 (0.55) | CDK9ALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL13883539 | 0.91 | CDK9 (0.55) | CDK9ALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL2401117 | 0.84 | POLB (0.51) | CDK9POLBMEN1KMT2ACCNT1 | |
| SCHEMBL12294012 | 0.84 | POLB (0.51) | CDK9POLBMEN1KMT2ACCNT1 | |
| SCHEMBL1850122 | 0.83 | CDK9 (0.52) | CDK9ALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL27800929 | 0.82 | FAAH (0.48) | CYP1A2CYP2D6CLK4USP2POLB | |
| SCHEMBL27821799 | 0.82 | FAAH (0.48) | CYP1A2CYP2D6CLK4USP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038516-A1 | Inhibitors of Protein Kinases | ASTRAZENECA AB (SE) | 2015-02-05 | — | — | US | disclosed |
| US-20150038516-A1 | Inhibitors of Protein Kinases | ASTRAZENECA AB (SE) | 2015-02-05 | — | — | US | disclosed |
| US-20150038516-A1 | Inhibitors of Protein Kinases | ASTRAZENECA AB (SE) | 2015-02-05 | — | — | US | disclosed |
| US-8716296-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2014-05-06 | — | — | US | disclosed |
| US-8716296-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2014-05-06 | — | — | US | disclosed |
| US-8716296-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2014-05-06 | — | — | US | disclosed |
| EP-2212297-B1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100249149-A1 | Inhibitors of Protein Kinases | ASTRAZENECA AB (SE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249149-A1 | Inhibitors of Protein Kinases | ASTRAZENECA AB (SE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249149-A1 | Inhibitors of Protein Kinases | ASTRAZENECA AB (SE) | 2010-09-30 | — | — | US | disclosed |
| EP-2212297-A1 | INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009047359-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047359-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249149-A1 | Inhibitors of Protein Kinases | CDK9, CDK19, CDK2 | CDK9 1/4885ALDH1A1 4732/4885CYP1A2 4600/4885 |
| US-20150038516-A1 | Inhibitors of Protein Kinases | CDK1, CDK2, CCNK | CDK9 22/4885ALDH1A1 3147/4885CYP1A2 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.